1. Home
  2. News
  3. Immutep Ltd
  4. New Patents Granted in Japan and South Korea for Efti
More Immutep Ltd news
Immutep LtdASX: IMM

New Patents Granted in Japan and South Korea for Efti

Nov 9, 2022 at 4:54 AM EST · Issued by Immutep Ltd

Filed with ASX · Nov 9, 2022 at 4:54 AM EST · 2 pages · English

On 6ix: 6ix.com/news/new-patents-granted-in-japan-and-south-korea-for-efti

Immutep Ltd on 6ix

In the deck

  • Immutep — Corporate Update (November 2022)25 slidesNov 10, 2022

Story so far

  • Fast Track granted by US FDA for Efti in 1st line NSCLCOct 4, 2022
  • Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1Aug 30, 2022
  • Efti with Keytruda shows encouraging activity in lung cancerMar 30, 2022

Earlier from Immutep

  • Late Breaking Abstract accepted for SITC Oral PresentationNov 2, 2022
  • Independent DMC recommends to continue TACTI-003 as plannedOct 25, 2022
  • Abstracts accepted for Presentation at SITC 2022Oct 5, 2022
  • Fast Track granted by US FDA for Efti in 1st line NSCLCOct 3, 2022
  • Immutep Receives A$2.7 million R&D French Tax IncentiveSep 22, 2022

Later from Immutep

  • Immutep Webcast to discuss clinical data presented at SITCNov 10, 2022
  • Immutep receives A$1 million R&D Tax IncentiveNov 13, 2022
  • Immutep enters 2nd collaboration with Pfizer and Merck KGaANov 28, 2022
  • GMP Manufacturing Process Developed for IMP761 LAG-3 AgonistDec 5, 2022
  • Commercial Scale in Manufacturing of Efti AchievedDec 7, 2022
All Immutep news releases↗

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer